Research programme: arrhythmia therapeutics - Merck

Drug Profile

Research programme: arrhythmia therapeutics - Merck

Alternative Names: DPO-1

Latest Information Update: 31 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class
  • Mechanism of Action Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Arrhythmias

Most Recent Events

  • 15 Dec 2009 Preclinical development is ongoing in USA
  • 05 Sep 2007 Data presented at the 234th American Chemistry Society National Meeting (234th-ACS-2007) added to the pharmacokinetics and Arrhythmias pharmacodynamics section
  • 02 Aug 2006 A preclinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top